EE03337B1 - Kiirestilahustuv galantamiinhüdrobromiiditablett - Google Patents

Kiirestilahustuv galantamiinhüdrobromiiditablett

Info

Publication number
EE03337B1
EE03337B1 EE9800429A EE9800429A EE03337B1 EE 03337 B1 EE03337 B1 EE 03337B1 EE 9800429 A EE9800429 A EE 9800429A EE 9800429 A EE9800429 A EE 9800429A EE 03337 B1 EE03337 B1 EE 03337B1
Authority
EE
Estonia
Prior art keywords
galantamine hydrobromide
fast soluble
hydrobromide tablet
tablet
soluble
Prior art date
Application number
EE9800429A
Other languages
English (en)
Estonian (et)
Inventor
Florent Victor De Cond Valentin
Marie Victor Gilis Paul
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE03337B1 publication Critical patent/EE03337B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
EE9800429A 1996-06-14 1997-06-06 Kiirestilahustuv galantamiinhüdrobromiiditablett EE03337B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201676 1996-06-14
PCT/EP1997/002986 WO1997047304A1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet

Publications (1)

Publication Number Publication Date
EE03337B1 true EE03337B1 (et) 2001-02-15

Family

ID=8224084

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800429A EE03337B1 (et) 1996-06-14 1997-06-06 Kiirestilahustuv galantamiinhüdrobromiiditablett

Country Status (33)

Country Link
US (2) US6099863A (de)
EP (1) EP0915701B1 (de)
JP (1) JP4172820B2 (de)
KR (1) KR100358676B1 (de)
CN (1) CN1102390C (de)
AR (2) AR008237A1 (de)
AT (1) ATE285777T1 (de)
AU (1) AU726212B2 (de)
BG (1) BG64168B1 (de)
BR (1) BR9709729A (de)
CA (1) CA2257431C (de)
CZ (1) CZ295226B6 (de)
DE (1) DE69732113T2 (de)
DK (1) DK0915701T3 (de)
EA (1) EA001193B1 (de)
EE (1) EE03337B1 (de)
ES (1) ES2235234T3 (de)
HK (1) HK1019703A1 (de)
HR (1) HRP970321B1 (de)
ID (1) ID17088A (de)
IL (1) IL127519A (de)
MY (1) MY121669A (de)
NO (1) NO322892B1 (de)
NZ (1) NZ333280A (de)
PL (1) PL189329B1 (de)
PT (1) PT915701E (de)
SI (1) SI0915701T1 (de)
SK (1) SK284620B6 (de)
TR (1) TR199802592T2 (de)
TW (1) TW506836B (de)
UA (1) UA62930C2 (de)
WO (1) WO1997047304A1 (de)
ZA (1) ZA975281B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
SI1140105T1 (en) 1998-12-24 2004-04-30 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
DK1660104T3 (da) * 2003-08-26 2010-06-21 Shire Holdings Ag Farmaceutisk formulering indeholdende lanthanforbindelser
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051489A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
EP2340813A1 (de) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Feste Darreichungsformen von Galantamin
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
CA2583439C (en) * 2004-09-24 2016-05-10 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US8168219B2 (en) * 2005-11-30 2012-05-01 Isp Investments Inc. Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
PL2010158T3 (pl) * 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
ATE545410T1 (de) 2008-05-09 2012-03-15 Ratiopharm Gmbh Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
WO2011067667A2 (en) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Fexofenadine microcapsules and compositions containing them
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN106822008A (zh) * 2017-01-11 2017-06-13 江苏艾兰得营养品有限公司 一种维生素d速溶制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
ATE285777T1 (de) 2005-01-15
ZA975281B (en) 1998-12-14
CN1222077A (zh) 1999-07-07
EP0915701A1 (de) 1999-05-19
DE69732113D1 (de) 2005-02-03
TW506836B (en) 2002-10-21
SI0915701T1 (en) 2005-06-30
EP0915701B1 (de) 2004-12-29
PL330431A1 (en) 1999-05-10
NO322892B1 (no) 2006-12-18
HK1019703A1 (en) 2000-02-25
CN1102390C (zh) 2003-03-05
HRP970321A2 (en) 1998-04-30
ES2235234T3 (es) 2005-07-01
DK0915701T3 (da) 2005-04-25
BG102991A (en) 1999-08-31
IL127519A0 (en) 1999-10-28
EA001193B1 (ru) 2000-12-25
BG64168B1 (bg) 2004-03-31
JP2000511918A (ja) 2000-09-12
MY121669A (en) 2006-02-28
NO985815D0 (no) 1998-12-11
HRP970321B1 (en) 2001-12-31
JP4172820B2 (ja) 2008-10-29
CZ295226B6 (cs) 2005-06-15
US6099863A (en) 2000-08-08
BR9709729A (pt) 1999-08-10
AR070670A2 (es) 2010-04-28
ID17088A (id) 1997-12-04
KR100358676B1 (ko) 2003-02-17
TR199802592T2 (xx) 1999-03-22
CZ403498A3 (cs) 1999-03-17
US6358527B1 (en) 2002-03-19
SK169698A3 (en) 1999-10-08
PT915701E (pt) 2005-05-31
AR008237A1 (es) 1999-12-29
IL127519A (en) 2002-07-25
AU726212B2 (en) 2000-11-02
SK284620B6 (sk) 2005-07-01
UA62930C2 (uk) 2004-01-15
NZ333280A (en) 1999-09-29
CA2257431A1 (en) 1997-12-18
PL189329B1 (pl) 2005-07-29
DE69732113T2 (de) 2005-12-08
AU3174397A (en) 1998-01-07
EA199900026A1 (ru) 1999-06-24
NO985815L (no) 1998-12-11
WO1997047304A1 (en) 1997-12-18
CA2257431C (en) 2001-11-20
KR20000015851A (ko) 2000-03-15

Similar Documents

Publication Publication Date Title
EE03337B1 (et) Kiirestilahustuv galantamiinhüdrobromiiditablett
ID24329A (id) Landasan lepas-pantai bergerak
DE69737936D1 (de) Arzneimittel
DE59707194D1 (de) Direkttablettierhilfsmittel
DE69730434D1 (de) Immunstimulierende lipidformulierung
BR9703096A (pt) Oscilador hidráulico
DE59706429D1 (de) Biegerichtmaschine
DE59706845D1 (de) Schlitzwandfräse
NL1006015A1 (nl) Toedieninrichting.
DE59703450D1 (de) Tablettenprüfgerät
DE29621865U1 (de) Portions-Tablette
NO983259L (no) Famciclovir tabletter
TR199700071A2 (tr) Tetrahidroizokinolin türevleri.
DE29820413U1 (de) Hydraulikeinrichtung
DE9401753U1 (de) Dichtungsbahn
DE29600830U1 (de) Dichtungsbahn
DE29623187U1 (de) Schachtunterteil
DE29619621U1 (de) Sockenständer
DE29618094U1 (de) Pharmazeutisches Präparat
ES1027529Y (es) Base de enchufe perfeccionada.
BR9604141A (pt) Conjunto móvel de britagem
BR7600438U (pt) Cortador de comprimidos
UA1246S (uk) Таблетка фармацевтична
IT241819Y1 (it) Tavoletta aspirante
NO954584D0 (no) Sokkelfundament

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231